SCHEMBL6489633

SCHEMBL6489633

C#CCN(CCc1cnccn1)C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 2/20 0.39
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
NLRP3 Q96P20 2/20 0.33
FGFR1 P11362 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
HPGD P15428 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
HIF1A Q16665 1/20 0.31
POLB P06746 2/20 0.30
TP53 P04637 1/20 0.30
MAOB P27338 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9315885 0.88 KMT2A (0.38) KMT2AMEN1ALDH1A1CDC7DBF4
SCHEMBL588637 0.81 KMT2A (0.37) KMT2AMEN1ALDH1A1CDC7DBF4
SCHEMBL9315853 0.71 ACHE (0.37) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1
SCHEMBL9316395 0.70 ALDH1A1 (0.35) ALDH1A1POLB
SCHEMBL2490236 0.70 KMT2A (0.47) KMT2AMEN1ALDH1A1CDC7DBF4
SCHEMBL981335 0.68 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1CDC7DBF4
SCHEMBL7518459 0.68 DPP4 (0.39) KMT2AMEN1ALDH1A1TSHR
SCHEMBL29269373 0.67 NLRP3 (0.42) KMT2AMEN1ALDH1A1CDC7DBF4
SCHEMBL5962677 0.67 CYP4F2 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2TDP1
SCHEMBL28148509 0.67 HSP90AA1 (0.33) ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951863-B2 Pyridoarylphenly oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-10-04 US disclosed
EP-1358185-A2 PYRIDOARYLPHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2003-11-05 EP disclosed
US-20030176422-A1 For therapy of bacterial infections in humans and animals ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-18 US disclosed
WO-2002064574-A2 PYRIDOARYLPHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176422-A1 For therapy of bacterial infections in humans and animals OXA1L, PIGS, NDUFS3 KMT2A 4609/4885MEN1 3703/4885ALDH1A1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.